German biotechnology company BioNTech SE (Nasdaq:BNTX), the development partner with Pfizer for a COVID-19 vaccine, on 24 September 2020 joined other leading COVID-19 vaccine developers in ruling out participation in Britain's plans to test experimental inoculations by deliberately infecting trial volunteers.
According to a spokesman of the company, "BioNTech's vaccine candidate is not part of this study."
Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.
AstraZeneca and Sanofi both have said their vaccine candidates were not involved in the programme, Reuters added.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma